A Multiple-Dose Study to Assess the Safety, Tolerability, and Steady State Pharmacokinetics of APD791 in Healthy Volunteers

Completed · Phase 1 · Has a placebo group

Conditions studied: Healthy

In brief

The APD791-002 study is designed primarily to evaluate the safety, tolerability, and pharmacokinetics of APD791 when administered for 7 days to healthy adult subjects.

Key facts

Study ID

NCT00619931

Run by

Arena Pharmaceuticals

People needed

50

Starts

2008-01-01

Expected to finish

2008-06-01

Last updated by the study team

2022-07-05

Who can join

Age: 19 and older, up to 45. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Healthy adult men and women, ages 19-45
• Non smokers

You may not qualify if…

• History of a bleeding disorder
• Use of any drug known to have an effect on coagulation or clotting or any anti-platelet therapy within 2 weeks of the screening
• Recently donated blood or had significant blood loss
• Current use of a prescription medication
• Pregnant females

Where it is running

• MDS Pharma Services — Lincoln, Nebraska, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.